| Literature DB >> 34645840 |
Shan Li1, Mei Chen1, Peng-Sheng Zheng2,3.
Abstract
The frequency and distribution of chromosomal abnormalities and the impact of parental chromosomal aberration on the pregnancy outcomes of couples with recurrent pregnancy loss remains controversial. 3235 RPL couples who experienced two or more miscarriages before 20 weeks were diagnosed in our tertiary referral hospital during 2008-2018 and included in the single-center retrospective cohort study covering a 10-year period. Chromosome aberration was detected in 121 (3.74%) among 3235 RPL couples which included 75 female and 46 male cases at an individual level. 101 cases were structural aberrations including balanced translocations in 46(38.0%) cases, Robertsonian translocations in 13(10.7%) cases, inversions in 42(34.7%) cases and 20(16.5%) cases were numerical aberrations. 121 carriers and 428 non-carriers were followed up for two years, 55 carriers and 229 non-carriers were subsequent pregnant after diagnosis by natural conception or intrauterine insemination. The frequency of carriers to have a health newborn was not significantly different with non-carriers (72.7% vs. 71.2%, adjusted P = 0.968). This study described the majority of carriers were balanced translocations and chromosome aberrations had a limited influence on live birth rate from the present data. The results of the study also remind us that natural conception may be also a good alternative rather than PGD (Pre-implantation Genetic Diagnosis) which is common in many other reproductive centers for such patients.Entities:
Mesh:
Year: 2021 PMID: 34645840 PMCID: PMC8514512 DOI: 10.1038/s41598-021-98606-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The flow chart presents the process of collecting abnormal chromosomal carriers from 5680 RPL couples in our Outpatient service.
Figure 2(A) The distribution of four aberrant types in the 121 RPL couples. (B) The respective numbers of female and male in the four aberrant type couples. (C) and (D). The distribution of four aberrant types in the 55 pregnancy and 66 non-pregnancy couples.
Figure 3The percents of aberrant chromosome No. in the balanced translocation and inversion RPL patients. (A) for balanced translocation and (B) for inversion.
Analysis of combined non-genetic etiological factors and live birth rate of 229 RM non-carriers and 55 carriers.
| Non-carriers (n = 229) | Carriers (n = 55) | Adjusted | ||
|---|---|---|---|---|
| Female age (years) | 30.75 ± 3.89 | 29.13 ± 3.40 | 0.0049* | – |
| Number of previous abortions | 2.42 ± 0.72 | 2.44 ± 0.63 | 0.865 | 0.912 |
| Primary RM | 84.3% (193/229) | 90.9% (51/55) | 0.18 | 0.807 |
| PCOS | 11.8% (27/229) | 10.9% (6/55) | 0.855 | 0.717 |
| DOR | 5.68% (13/229) | 5.45% (3/55) | 0.945 | 0.624 |
| Infection | 13.1% (30/229) | 14.6% (8/55) | 0.777 | 0.928 |
| Anatomical uterine abnormalities | 3.49% (8/229) | 3.64% (2/55) | 0.959 | 0.954 |
| Lymphocyte subgroup abnormalities | 24.5% (56/229) | 25.5% (14/55) | 0.877 | 0.553 |
| Endocrine disorders | 23.1% (53/229) | 16.4% (9/55) | 0.274 | 0.430 |
| Nutrition abnormalities | 14.8% (34/229) | 12.7% (7/55) | 0.688 | 0.490 |
| APL Abs | 34.9% (80/229) | 23.6% (13/55) | 0.109 | 0.086 |
| Connective tissue Abs | 10.9% (25/229) | 16.4% (9/55) | 0.264 | 0.324 |
| Subsequent Live birth rate | 71.2% (163/229) | 72.7% (40/55) | 0.819 | 0.968 |
Detailed chromosome karyotype of 55 RM carriers and their pregnancy outcomes.
| No | Age | Female chromosome | Male chromosome | No. of previous abortions | Pregnancy outcomes |
|---|---|---|---|---|---|
| 1 | 25 | 46, XX, t (6; 8) | 46, XY | 2 | Newborn health |
| 2 | 25 | 46, XX, t (6; 7) | 46, XY | 2 | Newborn health |
| 3 | 25 | 46, XX, t (2; 6) | 46, XY | 4 | Newborn health |
| 4 | 26 | 46, XX, t (8; 12) | 46, XY | 2 | Newborn health |
| 5 | 28 | 46, XX, t (4; 13) | 46, XY | 2 | Newborn health |
| 6 | 28 | 46, XX | 46, XY, t (5; 7) | 2 | Newborn health |
| 7 | 31 | 46, XX, t (6;18) | 46, XY | 2 | Newborn health |
| 8 | 27 | 46, XX, t (4; 14) | 46, XY | 2 | Newborn health |
| 9 | 24 | 46 XX, t (2; 3) | 46, XY | 4 | Newborn health |
| 10 | 32 | 46, XX, t (8; 9) | 46, XY | 2 | Newborn health |
| 11 | 28 | 46, XX, t (6; 9) | 46, XY | 2 | Newborn health |
| 12 | 30 | 46, XX, t (14; 21) | 46, XY | 3 | Newborn health |
| 13 | 27 | 46, XX, t (2; 4) | 46, XY | 4 | Newborn health |
| 14 | 30 | 46, XX | 46, XY, t (4; 21) | 2 | Newborn health |
| 15 | 26 | 46, XX | 46, XY, t (14; 22) | 2 | 7 W, miscarriage |
| 16 | 29 | 46, XX, t (3; 13) | 46, XY | 2 | 13-trisomy, odinopoeia |
| 17 | 28 | 46, XX, t (8; 15) | 46, XY | 3 | 7 W, miscarriage |
| 18 | 29 | 46, XX, t (8; 9) | 46, XY | 3 | 8 W, miscarriage |
| 19 | 24 | 46, XX | 46, XY, t (1; 8) | 2 | 6 W, miscarriage |
| 20 | 30 | 46, XX, t (8; 15) | 46, XY | 2 | 8 W, miscarriage |
| 21 | 23 | 46, XX, t (3;13) | 46, XY | 3 | 13- trisomy, odinopoeia |
| 22 | 27 | 46, XX | 46, XY, t (2, 12) | 2 | 20 W, miscarriage |
| 23 | 31 | 46, XX, t (2; 7) inv (9) | 46, XY | 4 | 7 W, miscarriage |
| 24 | 30 | 46, XX, inv (9) | 46, XY | 3 | Newborn health |
| 25 | 28 | 46, XX | 46, XY, inv (9) | 2 | Newborn health |
| 26 | 28 | 46, XX, inv (9) | 46, XY | 2 | Newborn health |
| 27 | 35 | 46, XX | 46, XY, inv (9) | 3 | Newborn health |
| 28 | 31 | 46, XX, inv (9) | 46, XY | 3 | Newborn health |
| 29 | 29 | 46, XX | 46, XY, inv(1) | 2 | Newborn health |
| 30 | 26 | 46, XX, inv (9) | 46, XY | 2 | Newborn health |
| 31 | 30 | 46, XX | 46, XY, inv (9) | 2 | Newborn health |
| 32 | 27 | 46, XX | 46, XY, inv (9) | 2 | Newborn health |
| 33 | 31 | 46, XX, inv (6) | 46, XY | 3 | Newborn health |
| 34 | 30 | 46, XX | 46, XY, inv (9) | 2 | Newborn health |
| 35 | 28 | 46, XX, inv (9) | 46, XY | 2 | Newborn health |
| 36 | 35 | 46, XX, inv (1) | 46, XY | 2 | Newborn health |
| 37 | 37 | 46, XX, inv (9) | 46, XY | 2 | Newborn health |
| 38 | 28 | 46, XX | 46, XY, inv (9) | 2 | Newborn health |
| 39 | 32 | 46, XX | 46, XY, inv (9) | 3 | Newborn health |
| 40 | 28 | 46, XX | 46, XY, inv (9) | 3 | Newborn health |
| 41 | 31 | 46, XX | 46, XY, inv (9) | 2 | 6 W, miscarriage |
| 42 | 29 | 46, XX | 46, XY, inv (9) | 2 | 14 W, miscarriage |
| 43 | 33 | 46, XX, inv (9) | 46, XY | 2 | 7 W, miscarriage |
| 44 | 31 | 46, XX | 46, XY, inv (9) | 2 | 21 W, miscarriage |
| 45 | 27 | 45, XO | 46, XY | 2 | Newborn health |
| 46 | 28 | 47, XX, +mar | 46, XY | 3 | Newborn health |
| 47 | 38 | 46, XX | 46, XY/46, XX(5%) | 3 | Newborn health |
| 48 | 35 | 46, XX [47]/45X, [3] | 46, XY | 3 | Newborn health |
| 49 | 24 | 46, XX | 47, XY, +mar | 3 | Newborn health |
| 50 | 38 | 45, X[3]/46, XX[57] | 46, XY | 3 | Newborn health |
| 51 | 30 | 45, X[3]/46, XX[97] | 46, XY | 2 | Newborn health |
| 52 | 30 | 46, XX | 47, XY, +mar | 2 | 8 W, miscarriage |
| 53 | 28 | 46, XX | 45, XY, rob (13; 14) | 2 | Newborn health |
| 54 | 27 | 45, XX, rob (13; 14) | 46, XY | 2 | Newborn health |
| 55 | 27 | 45, XX, rob (13; 14) | 46, XY | 3 | 7 W, miscarriage |
Figure 4The live birth rates in the non-carriers and carriers of four aberrant types.
Pregnancy outcomes of 34 RM couples with female carriers and 21 RM couples with male carriers.
| Female carriers (n = 34) | Male carriers (n = 21) | ||
|---|---|---|---|
| Female age (years) | 28.97 ± 3.01 | 29.09 + 2.72 | 0.879 |
| No. of previous abortions | 2.54 ± 0.71 | 2.24 ± 0.44 | 0.096 |
| Numerical abnormalities | 100.00% (5/5) | 66.67% (2/3) | 0.167 |
| Abnormal chromosome structures | 72.41% (21/29) | 66.67% (12/18) | 0.675 |
| Balanced translocations | 66.66% (12/18) | 40.00% (2/5) | 0.279 |
| Inversions | 88.89% (8/9) | 75.00% (9/12) | 0.423 |
| Robertsonian translocations | 50% (1/2) | 100% (1/1) | 0.386 |
| Total success rates | 76.47% (26/34) | 66.67% (14/21) | 0.428 |
Other relevant causes of 40 RM couples with live birth and 15 RM couples with miscarriage again.
| Carriers with live birth (n = 40) | Carriers with miscarriage again (n = 15) | ||
|---|---|---|---|
| Female age (years) | 29.35 ± 3.62 | 28.40 + 2.67 | 0.359 |
| No. of previous abortions | 2.43 ± 0.64 | 2.40 ± 0.63 | 0.897 |
| Infection | 15.00% (6/40) | 6.67% (1/15) | 0.658 |
| Anatomical uterine abnormalities | 2.50% (1/40) | 6.67% (1/15) | 0.475 |
| Autoimmune antibodies | 52.50% (21/40) | 60.00% (9/15) | 0.764 |
| Blocking antibody deficiency | 75.00% (30/40) | 53.33% (8/15) | 0.122 |
| Lymphocyte subgroup abnormalities | 27.50% (11/40) | 33.33% (5/15) | 0.671 |
| Endocrine disorders | 12.50% (5/40) | 13.33% (2/15) | 0.428 |
| Nutrition abnormalities | 22.50% (9/40) | 26.67% (4/15) | 0.746 |